#133: TheMachine: Gilead Announces $500 Million Accelerated Share Repurchase
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it entered... |
March 3, 2008
05:09:35 AM |
#132: NewsBot: GILD News Marketing Authorisation Application for Ambrisentan Validated by European Medicines Agency
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today... |
March 23, 2007
06:00:00 AM |
#131: NewsBot: GILD News SYSTIME Completes JD Edwards World Upgrade for Gilead Sciences On-Time and On-Budget
SAN FRANCISCO--(BUSINESS WIRE)--SYSTIME Computer Corporation announced today the... |
March 16, 2007
07:00:00 AM |
#130: NewsBot: GILD News Gilead Sciences to Present at the Lehman Brothers 10th Annual Global Healthcare Conference on Monday, March 19
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD)... |
March 15, 2007
01:30:00 PM |
#129: NewsBot: GILD News Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today... |
March 15, 2007
01:15:00 PM |
#128: NewsBot: GILD News Gilead Sciences Announces New Appointments within Executive Team
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD)... |
March 9, 2007
06:00:00 AM |
#127: NewsBot: GILD News Gilead Sciences to Present at the Cowen & Company 27th Annual Health Care Conference on Monday, March 12
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD)... |
March 8, 2007
01:30:00 PM |
#126: NewsBot: GILD News Gilead Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137
LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced... |
March 1, 2007
01:00:00 PM |
#125: NewsBot: GILD News Gilead Announces Completion of Phase II Clinical Trial of Novel Investigational HIV Integrase Inhibitor GS 9137
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today... |
February 23, 2007
01:00:00 PM |
#124: NewsBot: GILD News Gilead's New Drug Application for Ambrisentan Receives Priority Review Status
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today... |
February 16, 2007
01:00:00 PM |
#123: NewsBot: GILD News Carla A. Hills Joins Gilead Sciences' Board of Directors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)... |
January 23, 2007
05:45:00 AM |
#122: NewsBot: GILD News Gilead Sciences to Present at the 25th Annual JPMorgan Healthcare Conference on Monday, January 8th
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD)... |
January 4, 2007
01:15:00 PM |
#121: NewsBot: GILD News Gilead Announces Preliminary Results From Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today... |
December 19, 2006
01:30:00 PM |
#120: NewsBot: GILD News Gilead Submits New Drug Application To U.S. FDA for Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today... |
December 18, 2006
01:15:00 PM |
#119: NewsBot: GILD News 96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today... |
December 15, 2006
05:30:00 AM |
| 
| 
| 
| 
| 
| 
